Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Cognitive
Research dose range
Standard research range
250 - 500 mcg
Most consistently cited SC daily range across research-protocol sources.
Research focus
Stress/anxiety modulation, cognitive support
Observed window
Onset within hours
Administration
Once daily
Primary pathway
GABA-A subunit expression / Enkephalin pathway / BDNF
Dosing ranges compiled from research-protocol summaries and Russian clinical literature; not derived from a Western-replicated controlled dose-finding trial. For research use only.
PROTOCOL BENEFITS
◆
Shifts GABA-A receptor subunit expression toward calming, non-sedating patterns — engaging the inhibitory system at a different point than typical anxiolytics.
◆
Preserves endogenous enkephalin levels by inhibiting the enzymes that break them down, supporting the body's own stress-response chemistry.
◆
Upregulates BDNF in the hippocampus, connecting its calming profile to potential cognitive and neuroplasticity benefits rather than sedation alone.
SCIENCE
Selank is a synthetic heptapeptide — a stabilized analog of tuftsin, an immune-signaling peptide the body already makes. Developed in Russia and approved there as an anxiolytic since 2009, it's built for metabolic stability, extending its activity well beyond what the natural tuftsin fragment sustains on its own.
Rather than broadly potentiating GABA-A receptors the way conventional anxiolytics do, Selank appears to work upstream — shifting receptor subunit expression and slowing enkephalin breakdown instead of direct receptor agonism. The clinical evidence is real but limited in scale: Russian trials cover roughly 200 patients, and independent replication outside Russia is still limited.
WHAT TO EXPECT
Calming effects have been reported within hours in research models, consistent with Selank's short half-life. Cognitive and mood-related benefits are typically assessed over 2-4 week research cycles.
PROTOCOL NOTE
Available in 5mg. For research use only. Full documentation included with every order.
FAQ
Selank is studied for its effect on receptor subunit expression and enkephalin metabolism — a different entry point into the same system.
Trials come primarily from Russia, covering roughly 200 patients. Independent replication outside Russia remains limited — the evidence base is real but still developing.
